Understand the source comparison
Peptides for SIBO Treatment Protocol: Comparison
Ghrelin agonists (MK-677) Motilin receptor activation, MMC cycling restoration Moderate. Mechanistic studies in healthy subjects, no SIBO trials 10–25mg oral daily No controlled SIBO outcomes, variable individual response Strongest mechanistic rationale for mo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Ghrelin agonists (MK-677)
- Motilin receptor activation, MMC cycling restoration
- Moderate. Mechanistic studies in healthy subjects, no SIBO trials
- 10–25mg oral daily
- No controlled SIBO outcomes, variable individual response
- Strongest mechanistic rationale for motility-driven SIBO
- KPV (alpha-MSH fragment)
- Tight junction stabilization, anti-inflammatory signaling
- Low. In vitro and animal models only
- 500 mcg–2mg subcutaneous or oral
- No human SIBO data, absorption variability
- Best suited for barrier dysfunction hypothesis
- Thymosin alpha-1 / Thymalin
- Mucosal immune modulation, T-cell maturation
- Low. Extrapolated from hepatitis and sepsis studies
- 1.6mg subcutaneous twice weekly (thymosin alpha-1)
- Immune effects indirect, no gut-specific data
- Investigational for post-infectious immune dysregulation
- BPC-157
- Mucosal healing, angiogenesis, nitric oxide stabilization
- Very low. Animal models, no human trials
- 200–500 mcg subcutaneous or oral
- Dosing is empirical, human absorption unknown
- Popular but unvalidated; used post-eradication
- Dihexa
- Cognitive support, potential vagal nerve modulation
- Minimal. Primarily neurological focus
- 5–10mg oral (research only)
- No GI-specific studies, speculative mechanism
- Not recommended for SIBO protocols